Net profit of Shilpa Medicare rose 1014.29% to Rs 17.94 crore in the quarter ended September 2024 as against Rs 1.61 crore during the previous quarter ended September 2023. Sales rose 9.85% to Rs 343.80 crore in the quarter ended September 2024 as against Rs 312.98 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales343.80312.98 10 OPM %24.9018.66 - PBDT65.0536.96 76 PBT36.779.17 301 NP17.941.61 1014 Powered by Capital Market - Live News

Unicycive Therapeutics, Inc. (NASDAQ: UNCY) has announced that the U.S. Food and Drug Administration (USFDA) has accepted the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) and has set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025. If approved, OLC has the potential to meaningfully improve the treatment burden for hyperphosphatemia patients with chronic kidney disease (CKD) on dialysis. CKD patients on dialysis with hyperphosphatemia are often saddled with an onerous treatment regimen that includes having to take as many as 12 pills per day. OLC is likely to result in better patient adherence over currently available treatment options as it requires a lower pill burden in terms of the number and size of pills per dose, and the pills are swallowed instead of chewed for added convenience.Unicycive has entered into a long term manufacturing contract with Shilpa Medicare for the supply of the product at commercial scale once approved by the USFDA. With Unicycive`s NDA now under review, it is expected to commercialize and launch OLC in the US market in the second half of calendar year 2025.Powered by Capital Market - Live News

Shilpa Medicare will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live News

Shilpa Medicare`s 100% subsidiary, Shilpa Pharma Lifesciences received certificate of suitability (CEP) from EDQM (European Directorate for the Quality of Medicines & Healthcare) for API, Desmopressin. Desmopressin is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis. Desmopressin helps to reduce frequent urination and excessive thirst. This is used to treat central diabetes insipidus and bedwetting. Powered by Capital Market - Live News

Shilpa Medicare announced the appointment of Dr. Sridevi Khambhampaty, as Chief Executive Officer (CEO) of Shilpa Biologicals, a wholly owned subsidiary of Shilpa Medicare. The appointment is effective 19 September 2024 Powered by Capital Market - Live News